BRIEF-Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer

Oct 24 (Reuters) – Amgen Inc: * AMGEN: NEARLY 80% OF PATIENTS ON IMDELLTRA-IMFINZI ALIVE AT ONE YEAR VERSUS 53% WITH DURVALUMAB ALONE & PROGRESSION-FREE SURVIVAL MORE THAN TRIPLED * AMGEN: GRADE 3 OR

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)